The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The Executive Director of UNAIDS Winnie Byanyima is calling for accelerated global solidarity to strengthen Madagascar's response to HIV, including preventing new HIV infections and expanding access ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Expanded treatment options, increased naloxone distribution and targeted education campaigns likely led to a 37% reduction in ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...